Eton 76% Revenue Growth and 17 Straight Quarters of Sales Gains

Eton Pharmaceuticals (NASDAQ: ETON) reported strong Q1 2025 financial results with revenue of $17.3 million, including product sales of $14.0 million - a 76% growth over Q1 2024. The company marked its 17th consecutive quarter of sequential product sales growth. Key highlights include: - Successful relaunch of INCRELEX for rare pediatric endocrinology condition - Out-licensed INCRELEX international rights to Esteve Pharmaceuticals for $4.3M upfront - Relaunched GALZIN for Wilson disease with Eton Cares support program - Submitted NDA for ET-600 following positive clinical study results - Preparing for potential ET-400 launch with PDUFA date of May 28th - Posted Q1 GAAP EPS of $(0.06) and Non-GAAP EPS of $0.07 - Generated $2.1M operating cash flow with $17.4M cash on hand The company expects to exit 2025 at approximately $80M annual revenue run rate.

https://www.stocktitan.net/news/ETON/eton-pharmaceuticals-reports-first-quarter-2025-financial-x3gtuijis2dt.html